News

AlphaPrime integrates its AuroraPrime platform with OpenAI, enhancing clinical research with ChatGPT and exploring AGI applications in drug development.

May 9, 2023 — Singapore-based AlphaLife Sciences (referred to as "AlphaLife") announced the official integration of their clinical research cloud platform, AuroraPrime, with OpenAI's technology. This integration has enabled the practical application of ChatGPT in the digitalization and intelligence of clinical research. AlphaLife has already begun exploring and expanding the application scenarios with several well-known innovative drug development companies. Additionally, AlphaLife actively tests and fine-tunes the performance and effectiveness of various renowned AGI models in similar contexts, accelerating the exploration of large language models like ChatGPT in the field of clinical research.

AlphaLife & OpenAI

As a leading supplier of intelligent solutions for life science clinical research, AlphaLife has received strong support and assistance from Microsoft for Startups since its establishment in 2020. As a member of Microsoft for Startups' Founders Hub in early 2023, AlphaLife was invited to obtain priority access to OpenAI's developer tools and prototype testing. Subsequently, AlphaLife's AI technology team swiftly implemented the integration of AuroraPrime's underlying architecture with OpenAI and began practical application scenarios across multiple product lines, achieving significant milestones.

"ChatGPT is available across all platform products"

The AuroraPrime clinical research platform encompasses a variety of products to meet the diverse needs of digitalization throughout the entire clinical research process. Through the comprehensive integration with OpenAI, the operation interface of ChatGPT has been incorporated into all platform products. Users can directly interact with AI and seek assistance through the dialogue box. Additionally, the AlphaLife team has implemented automatic optimization and customization of professional content references to enhance the applicability and professionalism of ChatGPT generated results.

ChatGPT for Clinical Research Document Writing

Prime Create, a flagship product on the AuroraPrime platform, is a professional SaaS software specifically developed for the creation of life science clinical research documents, a scarce resource worldwide. With the support of OpenAI, the system's existing content assistance capabilities and scope have been further expanded, enabling enterprise users to conveniently access AI tools and improve content writing efficiency for clinical trial protocols, CSR reports, and more.

ChatGPT for Clinical Trial Project Management

Prime Coordinate is the latest innovative CTMS product released on the AuroraPrime platform. Built on AlphaPrime's in-house low-code platform, it offers high flexibility and scalability to meet the highly customized needs of different enterprises in clinical trial project management. With the assistance of OpenAI, enterprise CTMS systems are empowered with AI-driven features such as automated monitoring summary and intelligent planning reminders. Additionally, relevant compliance documents can be automatically generated based on actual results.

ChatGPT for Clinical Research Document Management

Prime Catalog is an enterprise-level document management system built on the AuroraPrime platform, which includes eTMF and project repositories, matching the multi-dimensional document management demands of enterprise-level and project-level documents, as well as project eTMF. With OpenAI's assistance, it can intelligently recommend the archival location for documents based on the project eTMF structure and uploaded document names, thereby enhancing overall document management efficiency.

ChatGPT for More

The intelligent capabilities announced in this integration with OpenAI represent only a portion of the initial exploration phase. The application of ChatGPT on the AuroraPrime platform will continue to iterate and update based on the practical needs of users. AlphaLife is currently deploying more related functionalities to explore the value of AI in practical application scenarios, empowering enterprise users to directly leverage OpenAI and enhance the efficiency of clinical research operations and management.

As the former team lead of Google China's Cloud AI and the Chief Business Architect at AlphaLife, Mr. Zhu Bogong stated, "The application of AI technology in the clinical research phase of life sciences has always been an active area of exploration and practice for the AlphaLife team. Since the emergence of ChatGPT at the end of 2022, the achievements of this new generation of AI technology have provided tremendous room for imagination for experts in the field of clinical research. These achievements are largely derived from the practical needs of reducing costs and increasing efficiency in clinical research operations and management. Digitization and intelligence are undoubtedly feasible paths that lead to the ultimate solution. With the convenience provided by Microsoft for Startups, AlphaLife has become one of the early adopters of OpenAI, deploying industry-level applications of ChatGPT. AlphaLife possesses leading technical capabilities in the industry and has successfully implemented practical application scenarios for ChatGPT at the product level in a short period of time. This makes AI no longer just a gimmick or a buzzword, but a practical tool that is within reach of life science innovation enterprises and beneficial to clinical trials."

About AlphaLife Sciences

AlphaLife Sciences Group focuses on the field of life sciences and consumer health, and is committed to creating a new generation of clinical research SaaS platform. It empowers innovative clinical trials and real-world research with world-leading technologies such as Cloud Services and AI .  AlphaLife is realizing process automation and intelligent decision-making driven by research doc and data ensures data consistency, improves operational efficiency, and accelerates innovative research and development in global life sciences and consumer health.